Petosemtamab secures a buyout for Merus
Genmab acquires the Dutch biotech for $8bn.
Genmab acquires the Dutch biotech for $8bn.
So who else could be interested in the oestrogen degrader?
As pivotal data approach, the French group pays $210m for ex-US rights.
Meanwhile, Royalty Pharma stakes $885m on $2.8bn sales by 2035.
Interius, one of the most advanced players, will cost $350m.